Utrecht/London March 20 2019 - Milabs B.V., manufacturer of the world’s only fully integrated SPECT/PET/Optical/CT-scanner, today announces that the core molecular imaging facility at Queen Mary University of London’s Barts Cancer Institute (BCI) has boosted its radionuclide imaging capabilities with a MILabs VECTor PET/SPECT/CT omni-tomography system. Unlike other multi-modality PET/SPECT/CT systems, the VECTor technology enables the acquisition of PET and SPECT images simultaneously, co-registered in space and time. The system can acquire high-resolution images of virtually all diagnostic and radiotherapy radionuclides, fused with anatomical details provided by fast, ultra-low dose X-ray CT.

Dr. Jane Sosabowski, BCI’s Cancer Imaging group leader, states: “At the BCI, our researchers are conducting pioneering research in a variety of areas, including targeting tumor cells and the tumor microenvironment to identify new therapies for cancer, all of which would benefit from using the in vivo translational imaging techniques offered by the MILabs VECTor PET/SPECT/CT omni-tomography system. We strive to keep our molecular imaging facility up-to-date with state-of-the-art imaging equipment, including the latest technology for diagnostic and radiotherapy imaging, to ensure that we continue to push the bounds of cancer research”

Dr. Frederik Beekman, founder and CEO comments: “We are very pleased that a growing number of renowned molecular imaging research institutes is appreciating the advanced capabilities of our new generation VECTor-6 in vivo small animal imaging systems. Features such as omni-tomography of PET and SPECT, multi-isotope PET and PET-SPECT, positron range free PET, imaging of virtually all radiotherapy isotopes including alpha and beta emitters at sub-mm resolutions, low dose ultra-high resolution in vivo CT with multi-gating and fluoroscopy are expanding the application reach of molecular imaging beyond traditional diagnostic procedures.”

About Barts Cancer Institute:
The BCI at Queen Mary University of London is one of the leading cancer institutes in the UK and, as part of the Cancer Research UK (CRUK) Barts Centre, is recognized as a CRUK Centre of Excellence and a key partner in the CRUK City of London Centre. By investing in and undertaking world-class research, the institute’s overriding objective is to ensure that research conducted at the BCI is relevant to and will impact on cancer patients. BCI’s research staff and students focus their efforts on how to reduce the burden of disease through prevention; increase the chances of survival through early detection and diagnosis; and improve patient survival through the discovery and development of more effective and innovative therapies. A wide range of research is currently
underway and includes:

• Understanding the genetics and evolution of cancer
• The development of novel molecular approaches for diagnosis
• Understanding the basic biology of tumor cells and the tumor microenvironment to identify new targets
for treatment
• Pre-clinical and clinical trials exploring new therapeutic strategies


About MILabs
MILabs has a history of providing a continuum of innovations to expand the applications of its multimodality imaging solutions used for the development of new diagnostic solutions and therapies. With its latest adaptive preclinical platform, MILabs has succeeded at commercializing a scalable imaging platform, able to accommodate PET, SPECT, Optical and CT imaging in a single integrated and user-friendly system. Awarded the Commercial Innovation of the Year 2018 at the Molecular Imaging Congress, this platform is globally recognized for being able to deliver the highest quality molecular, functional and anatomical images. For more information, visit: www.milabs.com or contact MILabs at info@milabs.com

European Press Room Homepage